-
2
pages
-
English
-
Documents
Description
Natural Bacteria May Provide New Way to Reduce Bad Cholesterol PR Newswire LOS ANGELES, Nov. 5, 2012 - New probiotic supplement Cardioviva™ presented at American Heart Association Scientific Sessions - This news release is featured in a news conference at 8 a.m. PT on Monday, Nov. 5, 2012 LOS ANGELES, Nov. 5, 2012 /PRNewswire/ -- Micropharma Limited today announced plans to launch Cardioviva™ (Lactobacillus reuteri NCIMB 30242), the world's only probiotic shown to naturally help reduce LDL-cholesterol, a risk factor for heart disease, by 11.6 percent in hypercholesterolemic adults. Micropharma will launch Cardioviva™ in Canada and in the U.S. in early 2013. The announcement was made after an American Heart Association (AHA) Scientific Sessions press conference today that discussed the new research regarding Cardioviva's ability to naturally lower "bad" and esterified cholesterol. The findings were also presented at a scientific session entitled "Probiotics for Heart Health: Next Generation of Adjunct Therapies for Lipid Management." The new evidence in support of Cardioviva not only suggests new potential causes of high cholesterol and methods for naturally managing it, but also adds to an emerging body of research on the gut microbiome (bacteria) and the essential role it plays in overall health.
-
Publié par
-
Langue
English